Sentry Investment Management LLC Takes $131,000 Position in AxoGen, Inc. (NASDAQ:AXGN)

Sentry Investment Management LLC acquired a new stake in shares of AxoGen, Inc. (NASDAQ:AXGN) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 19,138 shares of the medical equipment provider’s stock, valued at approximately $131,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC boosted its stake in AxoGen by 534.6% during the fourth quarter. Nisa Investment Advisors LLC now owns 7,805 shares of the medical equipment provider’s stock worth $53,000 after buying an additional 6,575 shares during the last quarter. Raymond James Financial Services Advisors Inc. boosted its position in AxoGen by 13.5% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 92,260 shares of the medical equipment provider’s stock valued at $630,000 after buying an additional 11,000 shares during the period. SG Americas Securities LLC raised its stake in shares of AxoGen by 45.9% in the fourth quarter. SG Americas Securities LLC now owns 14,823 shares of the medical equipment provider’s stock valued at $101,000 after acquiring an additional 4,666 shares in the last quarter. Vanguard Group Inc. boosted its holdings in AxoGen by 2.3% in the third quarter. Vanguard Group Inc. now owns 2,478,521 shares of the medical equipment provider’s stock valued at $12,393,000 after purchasing an additional 56,536 shares during the period. Finally, Deutsche Bank AG grew its stake in AxoGen by 15.3% during the 3rd quarter. Deutsche Bank AG now owns 25,641 shares of the medical equipment provider’s stock worth $128,000 after purchasing an additional 3,408 shares in the last quarter. 80.29% of the stock is currently owned by institutional investors.

Insider Transactions at AxoGen

In related news, CEO Karen L. Zaderej sold 39,280 shares of the company’s stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $7.68, for a total value of $301,670.40. Following the completion of the sale, the chief executive officer now owns 1,124,565 shares in the company, valued at approximately $8,636,659.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, VP Michael Patrick Donovan sold 36,310 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $8.81, for a total value of $319,891.10. Following the transaction, the vice president now owns 35,708 shares of the company’s stock, valued at $314,587.48. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Karen L. Zaderej sold 39,280 shares of AxoGen stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $7.68, for a total transaction of $301,670.40. Following the completion of the transaction, the chief executive officer now owns 1,124,565 shares in the company, valued at $8,636,659.20. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 111,201 shares of company stock worth $928,054. Insiders own 7.21% of the company’s stock.

Wall Street Analysts Forecast Growth

AXGN has been the subject of several analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $12.00 price target on shares of AxoGen in a report on Friday, January 19th. StockNews.com raised AxoGen from a “hold” rating to a “buy” rating in a research report on Wednesday, February 28th.

AxoGen Stock Down 0.9 %

Shares of AXGN opened at $6.94 on Thursday. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.89 and a quick ratio of 2.14. AxoGen, Inc. has a 1-year low of $3.45 and a 1-year high of $10.83. The firm has a fifty day moving average price of $8.74 and a 200 day moving average price of $7.28.

AxoGen (NASDAQ:AXGN) last announced its earnings results on Tuesday, March 5th. The medical equipment provider reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.11. The firm had revenue of $42.92 million during the quarter, compared to analysts’ expectations of $42.70 million. AxoGen had a negative return on equity of 22.38% and a negative net margin of 13.66%. Research analysts anticipate that AxoGen, Inc. will post -0.46 EPS for the current fiscal year.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.